Short answer
ICU MEDICAL INC/DE (ICUI) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $560M (up 4.4% year over year) with net income of $8M.
Q3 2026 key financials · XBRL
- Revenue
- $560M
- +4.4% YoY · +1.6% QoQ
- Net income
- $8M
- +120.0% YoY · +170.3% QoQ
- Operating margin
- 9.3%
- Gross margin
- 41.9%
- EPS (diluted)
- $1.06
- +857.1% YoY · +39.5% QoQ
Source: XBRL data from the ICU MEDICAL INC/DE (ICUI) Q3 2026 10-Q on SEC EDGAR. USD.
ICU MEDICAL INC/DE Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $560.4M, up from $537.0M YoY, driven by Infusion Systems growth
- Gross margin 41.9% vs 37.4% YoY, aided by $10.4M tariff refunds and price increases
- Best segment: Infusion Systems revenue $192.5M, up 10.7%; worst: Vital Care $69.5M, down 10.9%
- Cash $301.8M vs $308.0M at December 31, 2025; operating cash flow $218.6M year-to-date
- Capital deployment: $120.6M Term Loan B prepayments; 2026 capital expenditure outlook reduced to approximately $75M
- Near-term headwinds: tariffs, freight costs, oil prices, inflation, foreign exchange volatility and anticipated joint-venture impairment charges
Risk Factors
- No material changes to 2025 Form 10-K risk factors disclosed
- Carried-forward risks include medical-device regulatory compliance and product liability exposure
- Carried-forward risks include supply-chain disruption affecting device manufacturing
- Carried-forward risks include competition and healthcare-provider purchasing pressure
- Carried-forward risks include liquidity, debt, and foreign-currency exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ICU MEDICAL INC/DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.